{"id":10070,"date":"2023-07-25T12:30:25","date_gmt":"2023-07-25T12:30:25","guid":{"rendered":"https:\/\/www.dhenne-avocat.sea-dev-and-sun.fr\/?p=10070"},"modified":"2024-04-23T12:55:39","modified_gmt":"2024-04-23T12:55:39","slug":"apixaban-case-in-france-priority-to-the-patentee","status":"publish","type":"post","link":"https:\/\/www.dhenne-avocats.fr\/en\/apixaban-case-in-france-priority-to-the-patentee\/","title":{"rendered":"APIXABAN case in France: priority to the patentee"},"content":{"rendered":"<p>My British colleague has already commented brilliantly on the UK ruling in this case from the point of view of plausibility (see <a href=\"https:\/\/patentblog.kluweriplaw.com\/2023\/05\/11\/plausibility-post-g2-21-apixaban-in-the-uk\/\" data-wpel-link=\"internal\">here<\/a>). For my part, I\u2019d like to comment the French ruling in the same case, which takes the opposite view to the UK decision. We shall see that the French position is particularly pro-patent, more especially through the interpretation of the <strong>plausibility<\/strong> notion and of the priority right.<\/p>","protected":false},"excerpt":{"rendered":"<p>My British colleague has already commented brilliantly on the UK ruling in this case from the point of view of plausibility (see here). For my part, I\u2019d like to comment the French ruling in the same case, which takes the opposite view to the UK decision. We shall see that the French position is particularly [&hellip;]<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[29,16,28],"tags":[],"class_list":["post-10070","post","type-post","status-publish","format-standard","hentry","category-brevetabilite","category-brevets","category-pharmaceutique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>APIXABAN case in France: priority to the patentee - Dhenne Avocats<\/title>\n<meta name=\"description\" content=\"Lisez l&#039;article : APIXABAN case in France: priority to the patentee du blog Dhenne Avocats\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dhenne-avocats.fr\/en\/apixaban-case-in-france-priority-to-the-patentee\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"APIXABAN case in France: priority to the patentee - Dhenne Avocats\" \/>\n<meta property=\"og:description\" content=\"Lisez l&#039;article : APIXABAN case in France: priority to the patentee du blog Dhenne Avocats\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dhenne-avocats.fr\/en\/apixaban-case-in-france-priority-to-the-patentee\/\" \/>\n<meta property=\"og:site_name\" content=\"Dhenne Avocats\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-25T12:30:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-23T12:55:39+00:00\" \/>\n<meta name=\"author\" content=\"Mathilde Jean\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mathilde Jean\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/\"},\"author\":{\"name\":\"Mathilde Jean\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c\"},\"headline\":\"APIXABAN case in France: priority to the patentee\",\"datePublished\":\"2023-07-25T12:30:25+00:00\",\"dateModified\":\"2024-04-23T12:55:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/\"},\"wordCount\":79,\"publisher\":{\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#organization\"},\"articleSection\":[\"Brevetabilit\u00e9\",\"Brevets\",\"Pharmaceutique\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/\",\"url\":\"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/\",\"name\":\"APIXABAN case in France: priority to the patentee - Dhenne Avocats\",\"isPartOf\":{\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#website\"},\"datePublished\":\"2023-07-25T12:30:25+00:00\",\"dateModified\":\"2024-04-23T12:55:39+00:00\",\"description\":\"Lisez l'article : APIXABAN case in France: priority to the patentee du blog Dhenne Avocats\",\"breadcrumb\":{\"@id\":\"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.dhenne-avocats.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"APIXABAN case in France: priority to the patentee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#website\",\"url\":\"https:\/\/www.dhenne-avocats.fr\/\",\"name\":\"Dhenne Avocats\",\"description\":\"Cabinet d&#039;avocats en droit des brevets\",\"publisher\":{\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.dhenne-avocats.fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#organization\",\"name\":\"Dhenne Avocats\",\"alternateName\":\"dhenne avocats\",\"url\":\"https:\/\/www.dhenne-avocats.fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png\",\"contentUrl\":\"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png\",\"width\":512,\"height\":512,\"caption\":\"Dhenne Avocats\"},\"image\":{\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c\",\"name\":\"Mathilde Jean\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"caption\":\"Mathilde Jean\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"APIXABAN case in France: priority to the patentee - Dhenne Avocats","description":"Lisez l'article : APIXABAN case in France: priority to the patentee du blog Dhenne Avocats","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dhenne-avocats.fr\/en\/apixaban-case-in-france-priority-to-the-patentee\/","og_locale":"en_GB","og_type":"article","og_title":"APIXABAN case in France: priority to the patentee - Dhenne Avocats","og_description":"Lisez l'article : APIXABAN case in France: priority to the patentee du blog Dhenne Avocats","og_url":"https:\/\/www.dhenne-avocats.fr\/en\/apixaban-case-in-france-priority-to-the-patentee\/","og_site_name":"Dhenne Avocats","article_published_time":"2023-07-25T12:30:25+00:00","article_modified_time":"2024-04-23T12:55:39+00:00","author":"Mathilde Jean","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mathilde Jean","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#article","isPartOf":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/"},"author":{"name":"Mathilde Jean","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c"},"headline":"APIXABAN case in France: priority to the patentee","datePublished":"2023-07-25T12:30:25+00:00","dateModified":"2024-04-23T12:55:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/"},"wordCount":79,"publisher":{"@id":"https:\/\/www.dhenne-avocats.fr\/#organization"},"articleSection":["Brevetabilit\u00e9","Brevets","Pharmaceutique"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/","url":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/","name":"APIXABAN case in France: priority to the patentee - Dhenne Avocats","isPartOf":{"@id":"https:\/\/www.dhenne-avocats.fr\/#website"},"datePublished":"2023-07-25T12:30:25+00:00","dateModified":"2024-04-23T12:55:39+00:00","description":"Lisez l'article : APIXABAN case in France: priority to the patentee du blog Dhenne Avocats","breadcrumb":{"@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.dhenne-avocats.fr\/apixaban-case-in-france-priority-to-the-patentee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.dhenne-avocats.fr\/"},{"@type":"ListItem","position":2,"name":"APIXABAN case in France: priority to the patentee"}]},{"@type":"WebSite","@id":"https:\/\/www.dhenne-avocats.fr\/#website","url":"https:\/\/www.dhenne-avocats.fr\/","name":"Dhenne Avocats","description":"Cabinet d&#039;avocats en droit des brevets","publisher":{"@id":"https:\/\/www.dhenne-avocats.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dhenne-avocats.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.dhenne-avocats.fr\/#organization","name":"Dhenne Avocats","alternateName":"dhenne avocats","url":"https:\/\/www.dhenne-avocats.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png","contentUrl":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png","width":512,"height":512,"caption":"Dhenne Avocats"},"image":{"@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c","name":"Mathilde Jean","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","caption":"Mathilde Jean"}}]}},"_links":{"self":[{"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/posts\/10070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/comments?post=10070"}],"version-history":[{"count":0,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/posts\/10070\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/media?parent=10070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/categories?post=10070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/en\/wp-json\/wp\/v2\/tags?post=10070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}